OTLK · Forms 3, 4, 5
Insider trades at Outlook Therapeutics, Inc.
4 insiders bought $2.6M of Outlook Therapeutics, Inc. stock on the open market in the last 90 days.
Every Form 3, 4 and 5 filed for Outlook Therapeutics, Inc. (OTLK) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Kevin Michael Lundquist | Chief Financial Officer | Options or other derivatives | Form 4 | ||||
| Kevin Michael Lundquist | Chief Financial Officer | Became an insider (Form 3) | Form 3 | ||||
| Robert Charles Jahr | Chief Executive Officer | Buy | 151,515 | Form 4 | |||
| Lawrence A Kenyon | Chief Financial Officer | Buy | 101,010 | Form 4 | |||
| Ghiath M. Sukhtian | Director | Buy | 2,525,252 | $0.99 | $2.5M | Form 4 | |
| Faisal Ghiath Sukhtian | Director | Buy | 95,398 | $1.05 | $100K | Form 4 | |
| Lawrence A Kenyon | Chief Financial Officer | Options or other derivatives | Form 4 | ||||
| Robert Charles Jahr | Chief Executive Officer | Options or other derivatives | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.